Publications

Transplantation & Kidney Disease Publications

Fang, D. Y., B. Lu, S. Hayward, D. M. de Kretser, P. J. Cowan and K. M. Dwyer (2016). The Role of Activin A and B and the Benefit of Follistatin Treatment in Renal Ischemia-Reperfusion Injury in Mice. Transplantation Direct 2(7), e87.

Zhang, D., A. L. Gava, R. Van Krieken, N. Mehta, R. Li, B. Gao, E. M. Desjardins, G. R. Steinberg, T. Hawke and J. C. Krepinsky (2019). The caveolin-1 regulated protein follistatin protects against diabetic kidney disease. Kidney International [Epub ahead of print].

Mehta, N., A. L. Gava, D. Zhang, B. Gao and J. C. Krepinsky (2019). "Follistatin Protects Against Glomerular Mesangial Cell Apoptosis and Oxidative Stress to Ameliorate Chronic Kidney Disease." Antioxidants & redox signalling 31(8), 551-571.

Westall, G. P., G. I. Snell, M. Loskot, B. Levvey, R. O’Hehir, M. P. Hedger and D. M. de Kretser (2017). Activin Biology After Lung Transplantation. Transplantation Direct 3(6), e159.

de Kretser, D. M., J. G. Bensley, D. J. Phillips, B. J. Levvey, G. I. Snell, E. Lin, M. P. Hedger and R. E. O'Hehir (2016). Substantial Increases Occur in Serum Activins and Follistatin during Lung Transplantation. PLoS One 11(1), e0140948.

Snell, J. N., G. P. Westall and G. I. Snell (2015). The potential role of activin and follistatin in lung transplant dysfunction. Expert review of respiratory medicine 9(6): 697-701.

Chen, Y., C. Rothnie, D. Spring, E. Verrier, K. Venardos, D. Kaye, D. J. Phillips, M. P. Hedger and J. A. Smith (2014). Regulation and actions of activin A and follistatin in myocardial ischaemia–reperfusion injury. Cytokine 69(2), 255-262.

Marini, K. D., D. R. Croucher, R. A. McCloy, V. Vaghjiani, A. Gonzalez-Rajal, J. F. Hastings, V. Chin, A. Szczepny, K. Kostyrko, C. Marquez, W. S. N. Jayasekara, M. Alamgeer, V. Boolell, J. Z. R. Han, T. Waugh, H. C. Lee, S. R. Oakes, B. Kumar, C. A. Harrison, M. P. Hedger, N. Lorensuhewa, B. Kita, R. Barrow, B. W. Robinson, D. M. de Kretser, J. Wu, V. Ganju, E. A. Sweet-Cordero, A. Burgess, L. G. Martelotto, F. J. Rossello, J. E. Cain and D. N. Watkins (2018). Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Sci Transl Med 10(451).

Other Publications

Robertson DM, Klein R, de Vos FL, McLachlan RI, Wettenhall REH, Hearn MTW, Burger HG & de Kretser DM (1987) The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. Biochemical and biophysical research communications 149, 744-749. 

Hedger MP & de Kretser DM (2013). The activins and their binding protein, follistatin—Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine & Growth Factor Reviews 24, 285-295.

Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM & Phillips DJ (2007) Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proceedings of the National Academy of Sciences of the United States of America 104, 16239-16244.

Phillips DJ, de Kretser DM & Hedger MP (2009) Activin and related proteins in inflammation: not just interested bystanders. Cytokine & growth factor reviews 20, 153-164.

Jones KL, Brauman JN, Groome NP, de Kretser DM & Phillips DJ (2000) Activin A release into the circulation is an early event in systemic inflammation and precedes the release of follistatin. Endocrinology 141, 1905-1908.

de Kretser, D. M., J. G. Bensley, V. Pettilä, R. Linko, M. P. Hedger, S. Hayward, C. A. Allan, R. I. McLachlan, H. Ludlow and D. J. Phillips (2013). Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study. Critical care 17: R263.

Hardy CL, King SJ, Mifsud NA, Hedger MP, Phillips DJ, Mackay F, de Kretser DM, Wilson JW, Rolland KM & O’Hehir RE (2015). The activin A antagonist follistatin inhibits cystic fibrosis-like lung inflammation and pathology. Immunology and Cell Biology 93(6), 567-74.

Hardy CL, LeMasurier JS, Olsson F, Dang T, Yao J, Yang M, Plebanski M, Phillips DJ, Mollard R, Rolland JM & O’Hehir RE (2010) Interleukin-13 regulates secretion of the tumor growth factor-superfamily cytokine activin A in allergic airway inflammation. American journal of respiratory cell and molecular biology 42, 667-675.

Hardy CL, O’Connor AE, Yao J, Sebire K, de Kretser DM, Rolland JM, Anderson GP, Phillips DJ & O’Hehir RE (2006). Follistatin is a candidate endogenous negative regulator of activin A in experimental allergic asthma. Clinical and experimental allergy 36, 941-950.

Patella S, Phillips DJ, de Kretser DM, Evans LW, Groome NP & Sievert W (2001) Characterization of serum activin-A and follistatin and their relation to virological and histological determinants in chronic viral hepatitis. Journal of hepatology 34, 576-583.

Patella S, Phillips DJ, Tchongue J, de Kretser DM & Sievert W (2006) Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. American journal of physiology. Gastrointestinal and liver physiology 290, G137-G144.

Phillips DJ & de Kretser DM (1998) Follistatin: a multifunctional regulatory protein. Frontiers in neuroendocrinology 19, 287-322.

Rautela, J., L. F. Dagley, C. C. de Oliveira, I. S. Schuster, S. Hediyeh-Zadeh, R. B. Delconte, J. Cursons, R. Hennessy, D. S. Hutchinson, C. Harrison, B. Kita, E. Vivier, A. I. Webb, M. A. Degli-Esposti, M. J. Davis, N. D. Huntington and F. Souza-Fonseca-Guimaraes (2019). Therapeutic blockade of activin-A improves NK cell function and antitumor immunity. Science Signaling 12(596), eaat7527.

Lidbury BA, Kita B, Lewis DP, Hayward S, Ludlow H, Hedger MP & de Kretser DM. Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study. Journal of Translational Medicine 15(1), 1161-4.